Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Is there any upper limit of volume or shape of a prostate gland which would be a red flag to cytoreduce prior to treatment?
What is the upper limit of size you would consider offering a patient a five fraction regimen?
Answer from: Radiation Oncologist at Community Practice
Astro/aua consensus guidelines based on published data limits to 100cc or less
Comments
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This consensus statement is for SBRT
860
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Community Practice
No.
Sign In
or
Register
to read more
4362
4375
Related Questions
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
How would you treat a young man with a history of stage IA testicular pure seminoma s/p radical orchiectomy who has a solitary left inguinal lymph node recurrence and normal tumor markers?
How would you approach radiation for node-positive prostate cancer in a patient with an aortic and/or common iliac arterial aneurysm not meeting criteria for surgical repair?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?
Do you utilize daily enemas for patients undergoing prostate SBRT?
Is a larger prostate size or volume associated with a higher absolute PSA bounce after radiation?
How do you interpret nodes with minimal increased uptake on PSMA PET in prostate cancer?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
This consensus statement is for SBRT